InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,317.52
(
-0.07%
)
US TECH 100
18,232.80
(
0.00%
)
Dow Jones
39,819.58
(
-0.13%
)
Brent Oil
81.68
(
-0.93%
)
Bitcoin
69,797.15
(
-0.48%
)
Post# of 251889
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 829
Posts 119670
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 232402

Friday, 02/10/2023 8:59:04 AM

Friday, February 10, 2023 8:59:04 AM

Post# of 251889
BPMC—BLU-222 phase-1/2 trial subject_to partial clinical hold:

https://finance.yahoo.com/news/blueprint-medicines-announces-partial-clinical-130000611.html

Blueprint Medicines Corporation today announced that the U.S. Food and Drug Administration (FDA) verbally informed the company on February 8, 2023 that it has placed a partial clinical hold on the Phase 1/2 VELA trial of BLU-222 due to visual adverse events (AEs) observed in a limited number of patients. Patients currently enrolled in the trial are continuing on study drug at this time, and additional patients will not be enrolled until the partial clinical hold is resolved.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up